Genetic blueprint trial aims to outsmart rare cancers

NCT ID NCT03784014

Ongoing Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

Summary

This large study is testing whether analyzing a patient's tumor genetics can lead to more effective, personalized treatment for advanced soft-tissue sarcoma. About 600 patients will be randomly assigned to either receive treatment based on their genetic test results or receive standard treatment. The main goal is to see if this 'precision medicine' approach helps patients live longer without their cancer worsening compared to usual care.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CHU Poitiers

Poitiers, 86000, France
Centre Antoine Lacassagne

Nice, France
Centre Eugène Marquis

Rennes, 35042, France
Centre Georges François Leclerc

Dijon, France
Centre Henri Becquerel

Rouen, France
Centre Léon Bérard

Lyon, France
Centre Oscar Lambret

Lille, France
Hôpital Cochin

Paris, France
Hôpital Pitié Salpétrière

Paris, France
ICANS - Institut de Cancérologie Strasbourg

Strasbourg, 67033, France
IUCT Oncopôle

Toulouse, France
Institut Bergonie

Bordeaux, France
Institut Curie

Paris, France
Institut Gustave Roussy

Villejuif, France
Institut Paoli Calmettes

Marseille, France
Institut de Cancérologie de Montpellier

Montpellier, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau

Saint-Herblain, France

Conditions

Explore the condition pages connected to this study.

SOFT TISSUE SARCOMA